Kova’s most consequential contract distinction is not between its two advertised medications. It is between the first charge and the charges that follow. The platform’s terms condition collection of the initial plan payment on clinical eligibility and an initial prescription. After enrollment, however, scheduled recurring payments may be processed before another clinical review, refill request or prescription renewal is completed. For someone comparing subscriptions, that difference matters more than a broad promise of approval before payment might suggest.
This review examines Kova’s public documentation consulted October 19, 2026, with particular attention to who owes which service, what the advertised prices cover and what cancellation actually establishes. Kova markets access to compounded GLP-1 treatment, but LifeTech Apps Inc, its platform operator, says it does not provide medical or pharmacy services. The documentation explains substantial parts of enrollment and billing. It does not provide the complete cancellation and refund provisions needed to resolve every question about its longer plans.
At a glance
- Initial payment
- Kova may place an authorization hold, but its terms say the initial plan charge is not captured unless a provider determines clinical eligibility and issues the first prescription.Sources: [4]
- Recurring billing
- Later scheduled charges may precede clinical review, refill requests or prescription renewal; billing and medication shipments follow separate cycles.Sources: [4]
- Advertised monthly-plan prices
- Compounded semaglutide is advertised at $249 for the first month, then $299/month. Compounded tirzepatide is $299 for the first month, then renews at $399; that renewal line does not repeat the billing interval.Sources: [3]
- Included and separate costs
- Kova advertises consultations, prescription fulfillment, medication delivery, support and app access within the subscription, with no separate medication charge. Required laboratory work costs extra.Sources: [3]
The first prescription is a payment gate, not a rule for every renewal
Kova’s initial-enrollment language is reasonably specific. It may place a temporary authorization hold on the payment method, but says it will not capture the initial plan charge until a provider determines clinical eligibility and issues the initial prescription. If no initial prescription is issued, the hold is released or voided. That describes an authorization-and-capture process, rather than an unconditional charge followed by a promised refund. The documentation does not establish when a bank will display the released funds.
The recurring-payment provision changes the sequence. Once enrollment is complete, Kova says a scheduled charge may occur before subsequent clinical review, a refill request, prescription renewal or a dose change is completed. It expressly separates the plan’s billing cycle from reviews, prescriptions, refills and shipments. A renewal charge therefore does not, by itself, demonstrate that the next prescription has been approved or that a package is already moving through delivery.
Before enrolling, ask what happens when a recurring payment succeeds but the next prescription is delayed or not issued. The available excerpt does not settle the resulting credit or refund entitlement. Kova also says checkout or enrollment Plan Terms, confirmed in the order confirmation, control over inconsistent economic terms in its general financial section. Keeping those documents is especially important here; this guide to reviewing enrollment terms explains the distinctions worth recording.
The price menu offers choices, but does not settle the commitment
Kova publishes separate price schedules for compounded semaglutide and compounded tirzepatide. The one-month semaglutide plan begins at $249 for the first month and renews at $299/month. Tirzepatide begins at $299 for the first month and then “renews at $399”; that sentence does not repeat the renewal interval. Although listed under a one-month plan, the precise subsequent billing interval should be confirmed in the checkout terms rather than silently added to the quotation.
For the three-, six- and twelve-month options, the website presents a monthly amount or an upfront amount. These are advertised alternatives, not evidence that everyone must prepay the full duration. Equally, a monthly payment option does not establish that a longer plan can be ended without a remaining obligation. The table preserves both choices. The reviewed material does not identify exact product concentrations, presentations or which medication formulations are actually available by oral versus injectable route.
The missing commitment language matters most when comparing the longer options. A plan duration does not prove how much medication arrives in one shipment, and a payment interval does not establish the minimum contractual term. The complete checkout terms and order confirmation were not reviewed. Use the distinction between monthly prices and payment commitments to ask whether stopping future service also ends future charges, and whether any prepaid balance remains refundable.
| Advertised plan | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| One month | $249 first month; then $299/month | $299 first month; then renews at $399, with interval not repeated |
| Three months | $179/month or $537 upfront | $249/month or $747 upfront |
| Six months | $149/month or $894 upfront | $229/month or $1,374 upfront |
| Twelve months | $129/month or $1,548 upfront | $199/month or $2,388 upfront |
Cancellation is described; the full refund boundary is not
Kova’s website says customers can cancel at any time through the account page or by contacting support. Its more detailed explanation says access ends after the paid period: the active medication plan, upcoming refills, clinical care through the platform and companion app are then unavailable. It also says restarting may require a new clinical evaluation. Another website answer describes access ending on cancellation without the same timing detail, making written confirmation of the effective date useful.
Neither statement establishes a general right to recover money already paid. The reviewed terms excerpt omits text beginning at section 10.3, preventing a complete assessment of cancellation, refunds and possible obligations under multimonth plans. It would be inappropriate to fill that gap with either an assumed money-back guarantee or an assumed no-refund rule. The available documentation also does not establish a minimum notice deadline for avoiding the next scheduled charge.
A practical cancellation request should identify the plan, upcoming billing date and any pending refill, then ask for confirmation of the effective cancellation date and remaining financial obligations. Those are separate questions from whether the account remains usable through a paid period. The guide to cancellation notice and order status provides a framework for separating renewal cancellation from stopping an order already in progress. Kova’s incomplete terms make that separation particularly important.
The subscription spans several organizations
LifeTech Apps Inc operates the KOVA technology platform, including its app, website, accounts, portals and enrollment flows. Its terms expressly say the company does not provide medical, pharmacy or laboratory services. Clinical services instead belong to independent medical provider groups and their licensed healthcare professionals. The website identifies LifeTech Apps Inc with a registered office in Wilmington, Delaware; that corporate address does not establish where a particular clinician practices or which pharmacy will fill a prescription.
Kova says it works with Telegra’s provider network and names Laurie Mercier, MD, and nurse practitioners Kimberli Hastings, Theresa Vergara and Craig Sorkin. It also attributes a nationwide network of 503a and 503b compounding pharmacies to Telegra MD LLC. These are provider-published descriptions, not independent verification of credentials or pharmacy classifications. The listed pharmacy contacts include E-RxHub, Absolute Pharmacy, Southend Pharmacy, Strive Pharmacy and Pharmacy Boudreaux’s, without assigning a specific pharmacy to each prospective patient.
This division makes responsibility a necessary enrollment question: who handles an account charge, who makes the prescribing decision and who resolves a dispensing problem? Kova directs app inquiries to support@trykova.com and medication, prescription, refill and medical-care questions to the patient portal. Its organizational structure is not inherently proof of a service problem, but it makes a written map of provider responsibilities more useful than treating every interaction as a single company’s clinical promise.
What the bundled fee includes—and what remains separate
Kova describes the subscription as covering clinician consultations, prescription fulfillment, medication delivery, ongoing care support and full companion-app access. It says there is no separate charge for the medication itself. Another summary includes clinician review, prescription eligibility assessment, fulfillment coordination, educational resources and ongoing check-ins “where applicable.” That qualification matters: an included support category does not establish a fixed appointment schedule, a set number of check-ins or a guaranteed response time.
Laboratory work is a clear exclusion. Kova says a clinician may order tests and review results when needed, but the patient pays separately for the tests. Insurance is not required, and advertised pricing is the same regardless of insurance status. For FSA or HSA reimbursement, Kova directs customers to their plan provider. That is not a determination that a particular purchase qualifies, and the reviewed documentation does not establish reimbursement or insurance coverage for an individual.
The app is included with every plan at no extra cost, with advertised features such as reminders, injection-site logging, symptom tracking, protein tracking, history and education. Kova says features may change. Through the provider portal, patients can securely message the provider, request refills, track delivery and manage billing. These tools are useful documented components of the package, but their presence does not specify the frequency of clinician review or the speed of a refill decision.
Enrollment screens access; it does not guarantee a prescription
The intake asks about goals, medical history and preferences for injectable versus oral treatment. A licensed clinician reviews the intake online to determine whether GLP-1 medication is appropriate. Kova advertises access to compounded semaglutide and tirzepatide only when prescribed, and says no medication ships without provider approval. The questionnaire’s route preference does not confirm that both medications are available in both routes, nor does it establish an exact formulation a patient would receive.
Platform users must be at least 18, legally able to enter a binding contract and located in the United States. For clinical services, they must be physically in a state or territory where the applicable provider is authorized to practice. Kova advertises care and support across all 50 states, but qualifies specific service availability by licensure and state rules. Medication availability also depends on the state, pharmacy availability and provider judgment, so nationwide marketing is not an unconditional availability guarantee.
People already taking a GLP-1 must still complete medical intake so a provider can review their current treatment and history before deciding on continuity or transition. The documentation does not establish provider-specific BMI criteria, comorbidity requirements or detailed medical exclusions. It also does not provide numerical deadlines for review or approval. Those gaps are reasons to ask for an individualized clinical assessment and a service timeline, not reasons to infer eligibility or a guaranteed uninterrupted transfer.
Delivery terms give patients duties as well as remedies
Kova’s terms treat shipping and delivery dates as estimates affected by clinical review, pharmacy processing, product availability and carrier operations. They do not supply a numerical arrival guarantee. Patients must provide an accurate address, update it before shipment and promptly retrieve and store the package as the pharmacy instructs. Subject to applicable law, the terms treat a shipment as delivered when the carrier confirms delivery to the supplied address. That is a contractual delivery standard, not proof of proper temperature.
For an approved shipment claim, Kova says it may arrange a replacement at no additional charge. If replacement is not reasonably available, any applicable credit or refund depends on the financial section and Plan Terms. This is a conditional remedy, not a general refund guarantee. Dispensed products cannot be returned unless the pharmacy instructs otherwise. That return restriction is separate from whether an approved shipment claim qualifies for replacement or an applicable credit or refund. The reviewed record does not establish the full claim procedure or general refund rules. Asking who receives the complaint and what documentation is required would help clarify the process before a shipment problem occurs.
FDA guidance provides a separate safety boundary: do not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration; contact the provider or dispensing pharmacy to resolve the concern. That advice should not be displaced by a carrier’s delivery confirmation or an account’s billing status. FDA also reports measuring and administration errors with compounded products, some associated with hospitalization. Instructions should be clarified with the prescriber or pharmacist rather than reconstructed from a review.
Support, product status and privacy have distinct limits
Kova advertises 24/7 patient support from the medical provider, without a guaranteed response interval. Its terms expressly disclaim continuous monitoring of health, symptoms, medication use or platform activity. Messaging, reminders and symptom check-ins do not make the service an emergency or continuously monitored service. For contract evaluation, this is a meaningful boundary: ongoing access to a communication channel is different from an undertaking to detect a developing problem or initiate care without a patient request.
Kova acknowledges that compounded medications are not FDA approved or FDA-approved generics. FDA does not review compounded preparations for safety, effectiveness and quality before marketing. Nonapproval alone does not establish clinical inequivalence, and it does not validate or condemn this platform. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That context supports asking why a particular preparation is proposed, not assuming an ingredient name makes products interchangeable.
The privacy documentation adds another organizational detail: consumer health data may be shared with affiliate AM APPS LTD outside the United States for described operational purposes, subject to contractual and legal obligations. Also, the consulted document at the telehealth-consent address was titled Consumer Health Data Privacy Notice; it should not be treated as the actual medical consent. Prospective patients should obtain the applicable clinical consent and provider terms, neither of which was established by reviewing that privacy notice.
Questions & answers
Will Kova charge me if the initial clinician does not prescribe?
The terms say Kova will not capture the initial plan charge unless a provider finds you clinically eligible and issues the initial prescription. It may first place an authorization hold; without an initial prescription, that hold is released or voided. This protection is specifically about initial enrollment. Later recurring charges may occur before another review or prescription renewal is complete.
Must I pay the full twelve-month price upfront?
The website advertises alternatives: semaglutide at $129/month or $1,548 upfront, and tirzepatide at $199/month or $2,388 upfront for the twelve-month plan. It does not establish mandatory prepayment. However, monthly collection does not itself establish a month-to-month commitment. Ask for the complete plan terms showing any remaining payment obligation if you cancel before the advertised duration ends.
Does canceling Kova guarantee a refund?
No general refund guarantee can be established from the reviewed documentation. Kova describes cancellation through the account page or support and says access ends after the paid period. That does not establish repayment of unused prepaid amounts or elimination of any longer-plan obligation. The terms excerpt is incomplete at the relevant financial provisions, so obtain the applicable cancellation and refund policy in writing.
Which pharmacy will fill my Kova prescription?
The website lists E-RxHub, Absolute Pharmacy, Southend Pharmacy, Strive Pharmacy and Pharmacy Boudreaux’s, but the reviewed documentation does not identify which one would fill an individual order. Kova attributes pharmacy-network access to Telegra. Ask for the dispensing pharmacy’s identity and contact details before fulfillment, along with the specific product description and instructions. The network listing is not independent licensing verification.
Are lab tests and medication charged separately?
Kova says there is no separate medication charge within its advertised subscription, which also covers consultations, fulfillment, delivery, support and app access. Laboratory tests are different: if a clinician requires them, they are not included and must be paid separately. The public documentation does not provide a lab price schedule, so the subscription price alone does not establish the full cost of required care.
Where should I send a refill or treatment question?
Kova directs medication, prescription, refill and medical-care questions to the patient portal, which also supports secure provider messaging, delivery tracking and billing management. The published support@trykova.com address is for general companion-app inquiries. Although the medical provider advertises 24/7 support, no response deadline is documented, and the terms say the platform is neither continuously monitored nor an emergency service.
Our assessment
Kova documents useful parts of its offer: medication-specific prices, payment alternatives, bundled services, separate laboratory costs and a clear initial-prescription payment gate. It also discloses that recurring billing can run ahead of subsequent clinical and pharmacy steps. The central contractual weakness in this review is incomplete documentation of cancellation, refunds and longer-plan obligations—not proof that those policies are necessarily unfavorable. Before committing, obtain the full checkout terms, renewal schedule, cancellation deadline, refund boundaries and responsibilities of the assigned clinical group and pharmacy. Those records would make the advertised package meaningfully easier to evaluate.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.